Clinical Cancer Research, Vol 2, Issue 3 521-530, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Synergistic interaction between cisplatin and gemcitabine in vitro

AM Bergman, VW Ruiz van Haperen, G Veerman, CM Kuiper and GJ Peters
Department of Oncology, Free University Hos-pital, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands.

2',2'-Difluorodeoxycytidine (dFdC; gemcitabine) is a new antineoplastic agent that is active against ovarian carcinoma, non-small-cell lung carcinoma, and head and neck squamous cell carcinoma. cis-diamminedichloroplatinum (CDDP; cisplatin) is used commonly for the treatment of these tumors. Because the two drugs have mechanisms of action that might be complementary, we investigated a possible synergism between dFdC and CDDP on growth inhibition. The combination was tested in the human ovarian carcinoma cell line A2780, its CDDP-resistant variant ADDP and its dFdC-resistant variant AG6000, the human head and neck squamous cell carcinoma cell line UMSCC-22B, and the murine colon carcinoma cell line C26-10. The cells were exposed to dFdC and CDDP as single agents and to combinations in a molar ratio of 1:500 for 1, 4, 24, and 72 h with a total culture time of 72 h. Synergy was evaluated using the multiple drug effect analysis. In A2780 and ADDP cells, simultaneous exposure to the drugs for 24 and 72 h resulted in synergism, but shorter exposure times were antagonistic. No synergism was found in the UMSCC-22B and C26-10 cell lines at prolonged simultaneous exposure. However, a preincubation with CDDP for 4 h followed by a dFdC incubation for 1, 4, 24, and 72 h was synergistic in all cell lines except C26-10 cells. A 4-h preincubation with dFdC followed by an incubation with the combination for 20 and 68 h was synergistic in all cell lines. Initial studies of the mechanism of interaction concentrated on the effect of CDDP on dFdCTP accumulation and DNA strand break formation. In all cell lines, CDDP failed to increase dFdCTP accumulation at 4- or 24-h exposure to dFdC; in two cell lines, CDDP even tended to decrease dFdCTP accumulation. Neither dFdC nor CDDP caused more than 25% double strand break formation, whereas in the combination, CDDP even tended to decrease this type of DNA damage. The synergistic interaction between the two drugs is possibly the result of dFdC incorporation into DNA and/or CDDP-DNA adduct formation, which may be affected by each other.

This article has been cited by other articles:

				B. P. van Putte, M. Grootenboers, W.-J. van Boven, J. M. H. Hendriks, P. E. Y. van Schil, G. Guetens, G. De Boeck, G. Pasterkamp, F. Schramel, and G. Folkerts Pharmacokinetics of Gemcitabine when Delivered by Selective Pulmonary Artery Perfusion for the Treatment of Lung Cancer Drug Metab. Dispos., April 1, 2008; 36(4): 676 - 681. [Abstract] [Full Text] [PDF]

				D. H. Palmer, D. D. Stocken, H. Hewitt, C. E. Markham, A. B. Hassan, P. J. Johnson, J. A. C. Buckels, and S. R. Bramhall A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin Ann. Surg. Oncol., July 1, 2007; 14(7): 2088 - 2096. [Abstract] [Full Text] [PDF]

				E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, M. Del Tacca, and R. Danesi Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol. Cancer Ther., June 1, 2006; 5(6): 1387 - 1395. [Abstract] [Full Text] [PDF]

				A. H. Ko, E. Dito, B. Schillinger, A. P. Venook, E. K. Bergsland, and M. A. Tempero Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas J. Clin. Oncol., January 20, 2006; 24(3): 379 - 385. [Abstract] [Full Text] [PDF]

				C. M. S. P. Rocha Lima and A. M. Flores Gemcitabine Doublets in Advanced Pancreatic Cancer: Should We Move On? J. Clin. Oncol., January 20, 2006; 24(3): 327 - 329. [Full Text] [PDF]

				K.-H. Cho, Y.-B. Song, I.-S. Choi, E.-H. Cho, J.-W. Choi, Y. M. Ahn, Y. H. Roh, S.-H. Nam, and B.-S. Kim A Phase II Study of Single-Agent Gemcitabine as a Second-Line Treatment in Advanced Non-Small Cell Lung Cancer Jpn. J. Clin. Oncol., January 1, 2006; 36(1): 50 - 54. [Abstract] [Full Text] [PDF]

				R.M. Rudd, N.H. Gower, S.G. Spiro, T.G. Eisen, P.G. Harper, J.A.H. Littler, M. Hatton, P.W.M. Johnson, W.M.C. Martin, E.M. Rankin, et al. Gemcitabine Plus Carboplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer: A Phase III Randomized Study of the London Lung Cancer Group J. Clin. Oncol., January 1, 2005; 23(1): 142 - 153. [Abstract] [Full Text] [PDF]

				P. Sabbatini, C. Aghajanian, M. Leitao, E. Venkatraman, S. Anderson, J. Dupont, D. Dizon, C. O'Flaherty, J. Bloss, D. Chi, et al. Intraperitoneal Cisplatin with Intraperitoneal Gemcitabine in Patients with Epithelial Ovarian Cancer: Results of a Phase I/II Trial Clin. Cancer Res., May 1, 2004; 10(9): 2962 - 2967. [Abstract] [Full Text] [PDF]

				S. M. De Lange, C. J. van Groeningen, J. R. Kroep, A. Van Bochove, J. F. Snijders, G. J. Peters, H. M. Pinedo, and G. Giaccone Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer Ann. Onc., March 1, 2004; 15(3): 484 - 488. [Abstract] [Full Text] [PDF]

				J. R. Kroep, H. M. Pinedo, G. Giaccone, A. Van Bochove, G. J. Peters, and C. J. Van Groeningen Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer Ann. Onc., February 1, 2004; 15(2): 230 - 235. [Abstract] [Full Text] [PDF]

				T. Baetz, A. Belch, S. Couban, K. Imrie, J. Yau, R. Myers, K. Ding, N. Paul, L. Shepherd, J. Iglesias, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group Ann. Onc., December 1, 2003; 14(12): 1762 - 1767. [Abstract] [Full Text] [PDF]

				M. Crul, N. E. Schoemaker, D. Pluim, M. Maliepaard, R. W. M. Underberg, M. Schot, R. W. Sparidans, P. Baas, J. H. Beijnen, N. van Zandwijk, et al. Randomized Phase I Clinical and Pharmacologic Study of Weekly versus Twice-Weekly Dose-intensive Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., September 1, 2003; 9(10): 3526 - 3533. [Abstract] [Full Text] [PDF]

				M. A. Moufarij, D. R. Phillips, and C. Cullinane Gemcitabine Potentiates Cisplatin Cytotoxicity and Inhibits Repair of Cisplatin-DNA Damage in Ovarian Cancer Cell Lines Mol. Pharmacol., April 1, 2003; 63(4): 862 - 869. [Abstract] [Full Text] [PDF]

				R. V. N. Lord, J. Brabender, D. Gandara, V. Alberola, C. Camps, M. Domine, F. Cardenal, J. M. Sanchez, P. H. Gumerlock, M. Taron, et al. Low ERCC1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2002; 8(7): 2286 - 2291. [Abstract] [Full Text] [PDF]

				B. C. Kuenen, L. Rosen, E. F. Smit, M. R.N. Parson, M. Levi, R. Ruijter, H. Huisman, M. A. Kedde, P. Noordhuis, W. J.F. van der Vijgh, et al. Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors J. Clin. Oncol., March 15, 2002; 20(6): 1657 - 1667. [Abstract] [Full Text] [PDF]

				N. Van Zandwijk, E. F. Smit, G. W. P. Kramer, F. Schramel, S. Gans, J. Festen, A. Termeer, N. J. J. Schlosser, C. Debruyne, D. Curran, et al. Gemcitabine and Cisplatin as Induction Regimen for Patients With Biopsy-Proven Stage IIIA N2 Non-Small-Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955) J. Clin. Oncol., July 14, 2000; 18(14): 2658 - 2664. [Abstract] [Full Text] [PDF]

				D. Kaufman, D. Raghavan, M. Carducci, E. G. Levine, B. Murphy, J. Aisner, T. Kuzel, S. Nicol, W. Oh, and W. Stadler Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer J. Clin. Oncol., May 9, 2000; 18(9): 1921 - 1927. [Abstract] [Full Text] [PDF]

				W. Voigt, A. Bulankin, T. Müller, C. Schoeber, A. Grothey, C. Hoang-Vu, and H-J. Schmoll Schedule-dependent Antagonism of Gemcitabine and Cisplatin in Human Anaplastic Thyroid Cancer Cell Lines Clin. Cancer Res., May 1, 2000; 6(5): 2087 - 2093. [Abstract] [Full Text]

				L.-Y. Yang, L. Li, H. Jiang, Y. Shen, and W. Plunkett Expression of ERCC1 Antisense RNA Abrogates Gemcitabine-mediated Cytotoxic Synergism with Cisplatin in Human Colon Tumor Cells Defective in Mismatch Repair but Proficient in Nucleotide Excision Repair Clin. Cancer Res., March 1, 2000; 6(3): 773 - 781. [Abstract] [Full Text]

				L. Crino, A. M. Mosconi, G. Scagliotti, G. Selvaggi, S. Novello, M. Rinaldi, M. Della Giulia, C. Gridelli, A. Rossi, C. Calandri, et al. Gemcitabine as Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Phase II Trial J. Clin. Oncol., July 1, 1999; 17(7): 2081 - 2081. [Abstract] [Full Text] [PDF]

				A. Sandler and D. S. Ettinger Gemcitabine: Single-Agent and Combination Therapy in Non-Small Cell Lung Cancer Oncologist, June 1, 1999; 4(3): 241 - 251. [Abstract] [Full Text]

				N. Zeghari-Squalli, E. Raymond, E. Cvitkovic, and F. Goldwasser Cellular Pharmacology of the Combination of the DNA Topoisomerase I Inhibitor SN-38 and the Diaminocyclohexane Platinum Derivative Oxaliplatin Clin. Cancer Res., May 1, 1999; 5(5): 1189 - 1196. [Abstract] [Full Text] [PDF]

				L. H. Einhorn, M. J. Stender, and S. D. Williams Phase II Trial of Gemcitabine in Refractory Germ Cell Tumors J. Clin. Oncol., February 1, 1999; 17(2): 509 - 509. [Abstract] [Full Text] [PDF]

				C. J.A. van Moorsel, G. J. Peters, and H. M. Pinedo Gemcitabine: Future Prospects of Single-Agent and Combination Studies Oncologist, June 1, 1997; 2(3): 127 - 134. [Abstract] [Full Text] [PDF]